Theravance Biopharma
TBPH
128 hedge funds and large institutions have $422M invested in Theravance Biopharma in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 33 reducing their positions, and 15 closing their positions.
267% more call options, than puts
Call options by funds: $11K | Put options by funds: $3K
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
30% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 33
15% more capital invested
Capital invested by funds: $369M → $422M (+$53.5M)
8% more funds holding
Funds holding: 119 → 128 (+9)
2.26% less ownership
Funds ownership: 93.55% → 91.29% (-2.3%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$2.35M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.31M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$867K |
| 4 |
Millennium Management
New York
|
+$729K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$729K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management
Carouge,
Switzerland
|
-$5.55M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.26M |
| 3 |
Morgan Stanley
New York
|
-$942K |
| 4 |
AG
Algert Global
San Francisco,
California
|
-$851K |
| 5 |
Jane Street
New York
|
-$839K |
TBPH Hedge Fund Activity: Q4 2024 in Review
128 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2024, worth a combined $422M — up 15% from $369M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TBPH positions and 15 closed out — a net gain of 9 holders — while 43 added to existing stakes and 33 trimmed.
The largest buyer was Newtyn Management, adding an estimated $2.35M. The largest seller was Pictet Asset Management, exiting entirely with an estimated $5.55M sold.
- 128 institutional investors held Theravance Biopharma (TBPH) as of Q4 2024, up from 119 in Q3 2024.
- Funds reported $422M of Theravance Biopharma stock for Q4 2024, up 15% quarter-over-quarter.
- 24 funds opened new Theravance Biopharma positions in Q4 2024 and 15 closed out, a net change of +9 holders.
- The largest Theravance Biopharma buyer in Q4 2024 was Newtyn Management, an estimated $2.35M added.
- The largest Theravance Biopharma seller in Q4 2024 was Pictet Asset Management, an estimated $5.55M sold.
Based on aggregated 13F filings for Q4 2024.